If you looked at two snapshots of the same maple tree taken in July and December, you'd see a dramatic change from summer's ...

Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

Original Medicare and Medicare Advantage plans both cover certain types of approved stem cell therapy. Medicare Parts A and B, also known as Original Medicare, provide coverage for approved stem ...

(Ana-Maria Cujba/Wellcome Sanger Institute via AP) This image provided by Nathan Richoz shows a T cell aggregate in a human trachea biopsy on July 12, 2021, at the University of Cambridge in Cambridge ...

While B cell development in the birds’ primary B cell ... This is in line with downregulation of chB6 on CD40L induced plasmablasts (23) and lack of chB6 staining on plasma cells detected by ...

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.

B cells also exacerbate disease through the production of ... suggesting that CD19-positive plasmablasts and plasma cells are primary sources of these autoantibodies (98). However, the role of ...

WASHINGTON — The B-cell depleting agent inebilizumab (Uplizna) dramatically reduced the risk of flares and increased year-long remission of IgG4-related disease (RD), new research has found.